{"transactions":[{"id":743071,"issuer":{"id":5939,"kind":"organization","name":"Horizon Technology Finance Corp"},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-10T15:19:02.000Z","date":"2026-06-09","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":4.34,"value":434000.0,"ownership":{"direct":true},"balance_after":223527,"source":{"system":"sec-edgar","filing":"0001437749-26-020103","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487428/000143774926020103/rdgdoc.xml","form_type":"4"}},{"id":743070,"issuer":{"id":5939,"kind":"organization","name":"Horizon Technology Finance Corp"},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-10T15:19:02.000Z","date":"2026-04-14","kind":"grant","planned":false,"acquired":true,"shares":93527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired upon the completion of, and pursuant to, the transactions contemplated by the Agreement and Plan of Merger, dated as of August 7, 2025, by and among Horizon Technology Finance Corporation (\"HRZN\"), a Delaware corporation, Monroe Capital Corporation (\"MRCC\"), a Maryland corporation, HMMS, Inc., a Maryland corporation, Monroe Capital BDC Advisors, LLC, a Delaware limited liability company, and Horizon Technology Finance Management LLC, a Delaware limited liability company (the \"Merger Agreement\"). Pursuant to the Merger Agreement, each share of MRCC common stock, par value $0.001 per share, was converted into the right to receive 0.9402 shares of HRZN common stock, par value $0.001 per share. The market price of HRZN common stock at the close of trading on April 13, 2026, the last trading day prior to closing of the merger, was $4.57."}],"balance_after":103527,"source":{"system":"sec-edgar","filing":"0001437749-26-020103","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487428/000143774926020103/rdgdoc.xml","form_type":"4"}},{"id":808773,"issuer":{"id":5939,"kind":"organization","name":"Horizon Technology Finance Corp"},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-14T23:21:26.000Z","date":"2026-04-14","kind":"grant","planned":false,"acquired":true,"shares":93527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired upon the completion of, and pursuant to, the transactions contemplated by the Agreement and Plan of Merger, dated as of August 7, 2025, by and among Horizon Technology Finance Corporation (\"HRZN\"), a Delaware corporation, Monroe Capital Corporation (\"MRCC\"), a Maryland corporation, HMMS, Inc., a Maryland corporation, Monroe Capital BDC Advisors, LLC, a Delaware limited liability company, and Horizon Technology Finance Management LLC, a Delaware limited liability company (the \"Merger Agreement\"). Pursuant to the Merger Agreement, each share of MRCC common stock, par value $0.001 per share, was converted into the right to receive 0.9402 shares of HRZN common stock, par value $0.001 per share. The market price of HRZN common stock at the close of trading on April 13, 2026, the last trading day prior to closing of the merger, was $4.57."}],"balance_after":103527,"source":{"system":"sec-edgar","filing":"0001437749-26-012279","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487428/000143774926012279/rdgdoc.xml","form_type":"4"}},{"id":1328536,"issuer":{"id":5939,"kind":"organization","name":"Horizon Technology Finance Corp"},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-12-17T18:23:10.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":8.53,"value":170600.0,"ownership":{"direct":false,"nature":"By Self as Trustee for Michael P. Balkin Revocable Trust dated 11/1/93 as Amended"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the average price per share as of the transaction date. These shares were purchased in multiple transactions. Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder of the issuer."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001437749-24-037709","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487428/000143774924037709/rdgdoc.xml","form_type":"4"}},{"id":1440712,"issuer":{"id":5939,"kind":"organization","name":"Horizon Technology Finance Corp"},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-05T19:03:53.000Z","date":"2024-08-05","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":10.58,"value":105800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the average price per share as of the transaction date. These shares were purchased in multiple transactions. Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder of the issuer."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001437749-24-024617","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487428/000143774924024617/rdgdoc.xml","form_type":"4"}},{"id":2420771,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock Warrants (right to buy)","published_at":"2022-01-31T19:33:52.000Z","date":"2021-02-12","kind":"purchase","acquired":true,"shares":227500,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"The Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 227,500 Shares issuable upon exercise of such warrants held directly by the Sponsor."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 227,500 Shares issuable upon exercise of such warrants held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 227,500 Shares issuable upon exercise of such warrants held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":227500,"derivative":{"exercise_price":11.5,"exercise_date":"2022-02-12","expiration_date":"2027-12-03","underlying":"Class A Common Stock","underlying_shares":227500},"source":{"system":"sec-edgar","filing":"0001213900-22-004459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000121390022004459/ownership.xml","form_type":"4"}},{"id":2420770,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-31T19:33:52.000Z","date":"2022-01-28","kind":"purchase","acquired":true,"shares":15000,"price":4.83,"value":72450.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These 15,000 Shares (as defined below) were acquired in a single transaction through a self-directed individual retirement account of Mr. Balkin (as defined below)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"19,239 of these Shares are held directly by Mr. Balkin through a self-directed individual retirement account. \"Shares\" are shares of Class A Common Stock of the Issuer, par value $0.0001 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"7,526,025 of these Shares are held directly by Foresight Sponsor Group, LLC, a Delaware limited liability company (the \"Sponsor\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 7,526,025 Shares held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"19,239 of these Shares are held directly by Mr. Balkin through a self-directed individual retirement account. \"Shares\" are shares of Class A Common Stock of the Issuer, par value $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"7,526,025 of these Shares are held directly by Foresight Sponsor Group, LLC, a Delaware limited liability company (the \"Sponsor\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 7,526,025 Shares held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":7545264,"source":{"system":"sec-edgar","filing":"0001213900-22-004459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000121390022004459/ownership.xml","form_type":"4"}},{"id":2428487,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock Warrants (right to buy)","published_at":"2022-01-21T22:21:19.000Z","date":"2021-02-12","kind":"purchase","acquired":true,"shares":227500,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As previously reported by Mr. Balkin on February 17, 2021, the Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"As previously reported by Mr. Balkin on February 17, 2021, the Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 227,500 Shares issuable upon exercise of such warrants held directly by the Sponsor."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"As previously reported by Mr. Balkin on February 17, 2021, the Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 227,500 Shares issuable upon exercise of such warrants held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"As previously reported by Mr. Balkin on February 17, 2021, the Sponsor, simultaneously with the consummation of the Issuer's initial public offering on February 12, 2021 (the \"IPO\"), consummated the acquisition from the Issuer of 682,500 units (the \"Private Units\"), at a price of $10.00 per unit, in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consisted of one Share and one-third of one warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Such warrants acquired directly by the Sponsor on February 12, 2021, were exercisable for 227,500 Shares, provided that, at the time of issuance, such warrants could only be exercised during the period (i) commencing on the later of: (1) the date that is thirty (30) days after the first date on which the Issuer completed a business combination and (2) the date that is twelve (12) months from the consummation of the IPO and (ii) terminating at 5:00 p.m., New York City time, on the earlier to occur of (x) the date that is five (5) years after the date on which the Issuer completes its initial business combination or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Issuer completed a business combination on December 3, 2021, but the twelve (12) month anniversary of the consummation of the IPO is February 12, 2022. Accordingly, (i) such warrants will become exercisable on February 12, 2022, and (ii) the exercise period of such warrants will terminate at 5:00 p.m., New York City time, on the earlier to occur of (1) December 3, 2027, or (y) the liquidation of the Issuer in accordance with the Issuer's amended and restated certificate of incorporation, as amended from time to time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 227,500 Shares issuable upon exercise of such warrants held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":227500,"derivative":{"exercise_price":11.5,"exercise_date":"2022-02-12","expiration_date":"2027-12-03","underlying":"Class A Common Stock","underlying_shares":227500},"source":{"system":"sec-edgar","filing":"0001213900-22-003127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000121390022003127/ownership.xml","form_type":"4/A","original_submission_date":"2021-02-17"}},{"id":2428486,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-21T22:21:19.000Z","date":"2022-01-19","kind":"purchase","acquired":true,"shares":4239,"price":5.1,"value":21618.9,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These 4,239 Shares (as defined below) were acquired in a single transaction through a self-directed individual retirement account of Mr. Balkin (as defined below)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"4,239 of these Shares are held directly by Mr. Balkin through a self-directed individual retirement account. \"Shares\" are shares of Class A Common Stock of the Issuer, par value $0.0001 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"7,526,025 of these Shares are held directly by Foresight Sponsor Group, LLC, a Delaware limited liability company (the \"Sponsor\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 7,526,025 Shares held directly by the Sponsor."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"4,239 of these Shares are held directly by Mr. Balkin through a self-directed individual retirement account. \"Shares\" are shares of Class A Common Stock of the Issuer, par value $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"7,526,025 of these Shares are held directly by Foresight Sponsor Group, LLC, a Delaware limited liability company (the \"Sponsor\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Michael P. Balkin, a citizen of the United States (\"Mr. Balkin\"), is the sole manager of the Sponsor. Consequently, Mr. Balkin has voting and investment power over the securities held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As a result of having voting and investment power over the securities held directly by the Sponsor, Mr. Balkin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the 7,526,025 Shares held directly by the Sponsor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Mr. Balkin disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":7530264,"source":{"system":"sec-edgar","filing":"0001213900-22-003127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000121390022003127/ownership.xml","form_type":"4/A","original_submission_date":"2021-02-17"}},{"id":2546827,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2021-10-06T21:25:54.000Z","date":"2021-10-04","kind":"exercise","acquired":false,"shares":6843525,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of Class B common stock have no expiration date and will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment as set forth in the Issuer's registration statement on Form S-1 (File No. 333-251978)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A common stock of the Issuer acquired upon conversion of shares of Class B common stock of the Issuer at the Sponsor's election."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A common stock of the Issuer acquired upon conversion of shares of Class B common stock of the Issuer at the Sponsor's election."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Class B common stock have no expiration date and will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment as set forth in the Issuer's registration statement on Form S-1 (File No. 333-251978)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Class B common stock have no expiration date and will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment as set forth in the Issuer's registration statement on Form S-1 (File No. 333-251978)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Foresight Sponsor Group, LLC (the \"Sponsor\"). The Sponsor is governed by a board of managers consisting of Greg Wasson and Michael Balkin. Each of Mr. Wasson and Mr. Balkin disclaims beneficial ownership of the securities held by the Sponsor except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":6843525},"source":{"system":"sec-edgar","filing":"0000899243-21-039472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000089924321039472/doc4.xml","form_type":"4"}},{"id":2546826,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2021-10-06T21:25:54.000Z","date":"2021-10-04","kind":"exercise","acquired":true,"shares":6843525,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A common stock of the Issuer acquired upon conversion of shares of Class B common stock of the Issuer at the Sponsor's election."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A common stock of the Issuer acquired upon conversion of shares of Class B common stock of the Issuer at the Sponsor's election."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Foresight Sponsor Group, LLC (the \"Sponsor\"). The Sponsor is governed by a board of managers consisting of Greg Wasson and Michael Balkin. Each of Mr. Wasson and Mr. Balkin disclaims beneficial ownership of the securities held by the Sponsor except to the extent of his pecuniary interest therein."}],"balance_after":7526025,"source":{"system":"sec-edgar","filing":"0000899243-21-039472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000089924321039472/doc4.xml","form_type":"4"}},{"id":2853099,"issuer":{"id":4562,"kind":"organization","name":"P3 Health Partners Inc."},"owners":[{"id":39659,"kind":"person","name":"Balkin Michael","position":1,"cik":"0001843078","reported_name":"Balkin Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2021-02-17T23:12:42.000Z","date":"2021-02-12","kind":"purchase","acquired":true,"shares":682500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Simultaneously with the Issuer's initial public offering, Foresight Sponsor Group, LLC (the \"Sponsor\") acquired, at a price of $10.00 per unit, 682,500 units (the \"Private Units\") in a private placement for an aggregate purchase price of $6,825,000. Each Private Unit consists of one share of common stock and one-third of one warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the Sponsor. The Sponsor is governed by a board of managers consisting of Greg Wasson and Michael Balkin. Each of Mr. Wasson and Mr. Balkin disclaims beneficial ownership of the securities held by the Sponsor except to the extent of his pecuniary interest therein."}],"balance_after":682500,"source":{"system":"sec-edgar","filing":"0000899243-21-006961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832511/000089924321006961/doc4.xml","form_type":"4"}}]}